Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma

59Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) still remains a lethal malignancy benefiting from the identification of the new target for early detection and/or development of new therapeutic regimens based on a better understanding of the biological mechanism for treatment. The overexpression of Her2 and Her3 receptors have been identified in various solid tumors, but its prognostic relevance in HNSCC remains controversial.Methods: Three hundred eighty-seven primary HNSCCs, 20 matching metasis and 17 recurrent HNSCCs were arrayed into tissue microarrays. The relationships between Her2 and Her3 protein expression and clinicopathological parameters/survival of HNSCC patients were analyzed with immunohistochemistry.Results: Her3 is detected as either a cytoplasmic or a membranous dominant expression pattern whereas Her2 expression showed uniform membranous form. In primary tumor tissues, high membranous Her2 expression level was found in 104 (26.9%) cases while positive membranous and cytoplasmic Her3 expression was observed in 34 (8.8%) and 300 (77.5%) samples, respectively. Membranous Her2 expression was significantly associated with histological grade (P = 0.021), as grade 2 tumors showed the highest positive expression. Membranous Her3 over-expression was significantly prevalent in metastatic tissues compared to primary tumors (P = 0.003). Survival analysis indicates that membranous Her3 expression is significantly associated with worse overall survival (P = 0.027) and is an independent prognostic factor in multivariate analysis (hazard ratio, 1.51; 95% confidence interval, 1.01-2.23; P = 0.040).Conclusions: These results suggest that membranous Her3 expression is strongly associated with poor prognosis of patients with HNSCC and is a potential candidate molecule for targeted therapy. © 2011 Takikita et al; licensee BioMed Central Ltd.

References Powered by Scopus

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

6638Citations
N/AReaders
Get full text

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial

6210Citations
N/AReaders
Get full text

Tissue microarrays for high-throughput molecular profiling of tumor specimens

3652Citations
N/AReaders
Get full text

Cited by Powered by Scopus

HER3 overexpression and survival in solid tumors: A meta-analysis

177Citations
N/AReaders
Get full text

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

64Citations
N/AReaders
Get full text

HER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting

61Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Takikita, M., Xie, R., Chung, J. Y., Cho, H., Ylaya, K., Hong, S. M., … Hewitt, S. M. (2011). Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. Journal of Translational Medicine, 9(1). https://doi.org/10.1186/1479-5876-9-126

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

56%

Researcher 10

40%

Professor / Associate Prof. 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 13

48%

Agricultural and Biological Sciences 8

30%

Biochemistry, Genetics and Molecular Bi... 5

19%

Pharmacology, Toxicology and Pharmaceut... 1

4%

Save time finding and organizing research with Mendeley

Sign up for free